1. Search Result
Search Result
Results for "

IFN-g

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Peptides

2

Inhibitory Antibodies

19

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99292

    HuZAF; Anti-Human IFNG Recombinant Antibody

    IFNAR Inflammation/Immunology
    Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
    Fontolizumab
  • HY-RS06587

    Small Interfering RNA (siRNA) Others

    IFNG Human Pre-designed siRNA Set A contains three designed siRNAs for IFNG gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IFNG Human Pre-designed siRNA Set A
    IFNG Human Pre-designed siRNA Set A
  • HY-117786

    PKC Neurological Disease
    Go 7874 is a protein kinase C (PKC) inhibitor. Go 7874 mediated neuroprotection against LPS/IFNg-induced neuronal cell death in an immune-mediated neurotoxicity model, not through PKC activity. In contrast, the neuroprotective mechanism of Go 7874 involves inhibition of inducible nitric oxide synthase (iNOS) gene expression, followed by reduced nitric oxide (NO) production .
    Go 7874
  • HY-P10497

    Bacterial Others
    EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases .
    EBV BZLF1 (190-197)
  • HY-144395

    HDAC Apoptosis Inflammation/Immunology Cancer
    HDAC6-IN-4 (C10) is a potent, orally active and highly selective HDAC6 inhibitor with an IC50 value of 23 nM. HDAC6-IN-4 induces cancer cells apoptosis and shows significant antitumor efficacy, without obvious toxicity .
    HDAC6-IN-4
  • HY-149916

    Adenosine Receptor Cancer
    A2AR-antagonist-1 (compound 38) is an orally active adenosine A2A receptor (A2AR) antagonist (IC50=29 nM). A2AR-antagonist-1 exhibits anti-tumor activity and mouse liver microsomal metabolic stability (t1/2=86.1 min). A2AR-antagonist-1 is also a T cells activator, via inhibiting immunosuppressive molecules (LAG-3 and TIM-3) and enhancing effector molecules (GZMB, IFNG, and IL-2) .
    A2AR-antagonist-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: